ArticleEJHaem2025
TRBC1/TRBC2 Immunophenotyping Provides Added Value During the Diagnostic Workup of T-Cell Lymphoma.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Special Issue "Flow Cytometry: Applications and Challenges".International journal of molecular sciences · 2026Article
- TRBC1/TRBC2 Immunophenotyping Provides Added Value During the Diagnostic Workup of T-Cell Lymphoma.EJHaem · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Molecular T-cell receptor (TCR) clonality testing cannot link clonality to immunophenotype, limiting discrimination between malignant and clonal reactive T-cell expansions. Methods: We evaluated TRBC1/TRBC2 immunophenotyping in 50 consecutive cases with suspected T-cell malignancy, assessing restriction (ratio > 10) across T-cell subsets. Results: TRBC immunophenotyping showed 100% sensitivity for T-cell malignancy if assessed within subsets or phenotypically abnormal populations. Malignant clones predominantly showed CD4αβ/CD8αβ restriction (18/21), while reactive clones predominantly showed γδ/dual-positive/dual-negative restriction (15/16), enabling enhanced discrimination. Conclusion: TRBC immunophenotyping provides sensitive clonality detection with phenotypic lineage assignment, adding diagnostic clarity beyond molecular testing and supporting integration into routine workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.